Study of TAK-188, an Anti-CCR8 Antibody-Drug Conjugate, for Adults with Advanced or Metastatic Solid Tumors

What this Trial Is About

Researchers are evaluating TAK-188, a new medicine targeting a protein called CCR8 found on certain tumor cells that weaken the bodys immune response. This trial focuses on adults with advanced or metastatic solid tumors that have not improved with standard treatments. The study aims to assess the safety, tolerability, and effectiveness of TAK-188 in helping the immune system fight these cancers. Participants receive TAK-188 as an intravenous infusion in escalating doses during 21-day treatment cycles, with infusions on Days 1, 8, and 15. Depending on the type of cancer, dosing schedules may vary, including once weekly or once every two weeks, continuing for up to 12 months. Different groups include those with head and neck cancer, non-small cell lung cancer, and gastroesophageal adenocarcinoma, each receiving TAK-188 at recommended doses determined during the trial. During the study, participants undergo evaluations for side effects and response to treatment, including blood tests, biopsies, and imaging scans. Researchers monitor immune cell changes and drug levels. After treatment ends, participants health is followed for up to one year to observe long-term effects. The main outcomes measured include safety events, tumor response rates, and disease control over up to 24 months.

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors